• The shares have fallen off lately, but this happens on a news-driven stock.
• It’s an attractive risk/reward play but the underlying story warrants patience but we still think that will pay off.
• MRTP status is the obvious catalyst to come, with FDA regulation of nicotine levels further out.
• Its quest for MRTP status is significantly enhanced by the FDA plans to mandate nicotine levels and will open up lots of commercial opportunities.

Source: SHU Portfolio: An Update On 22nd Century Group – 22nd Century Group, Inc. (NYSEMKT:XXII) | Seeking Alpha